is a Japanese

pharmaceutical company The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate sympt ...

headquartered in

Tokyo Tokyo (; ja, 東京, , ), officially the Tokyo Metropolis ( ja, 東京都, label=none, ), is the capital and largest city of Japan. Formerly known as Edo, its metropolitan area () is the most populous in the world, with an estimated 37.46 ...

, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and

Nikkei 225 The Nikkei 225, or , more commonly called the ''Nikkei'' or the ''Nikkei index'' (), is a stock market index for the Tokyo Stock Exchange (TSE). It has been calculated daily by the '' Nihon Keizai Shimbun'' (''The Nikkei'') newspaper since 19 ...

stock indices In finance, a stock index, or stock market index, is an index that measures a stock market, or a subset of the stock market, that helps investors compare current stock price levels with past prices to calculate market performance. Two of the ...

History

Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. The American subsidiary of the company, Eisai Inc., was established in 1995. On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept ( donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (

rabeprazole Rabeprazole, sold under the brand name Aciphex, among others, is a medication that decreases stomach acid. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and excess stomach acid production such as in Zollinger–Elli ...

), a drug co-marketed with Johnson & Johnson. In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals. In April 2007, Eisai acquired

Exton, Pennsylvania Exton is a census-designated place (CDP) in West Whiteland Township, Chester County, Pennsylvania, United States. Its population was 5,622 at the 2020 census. The Exton Square Mall and Main Street at Exton are both located within Exton along w ...

-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases. In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for US$3.9 billion. This event brought Dacogen ( decitabine), Aloxi ( palonosetron), Hexalen ( altretamine) for ovarian cancer, and the Gliadel Wafer (

carmustine Carmustine, sold under the brand name BiCNU among others, is a medication used mainly for chemotherapy. It is a nitrogen mustard β-chloro- nitrosourea compound used as an alkylating agent. Description Carmustine is an orange-yellow solid medic ...

) for brain tumors into the Eisai product portfolio. In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel.

Locations

Eisai Co., Ltd. is based in

, Japan, while its American subsidiary Eisai Inc. is headquartered in Nutley, New Jersey. Eisai maintains medical research headquarters in Nutley as well as at locations in

Japan Japan ( ja, 日本, or , and formally , ''Nihonkoku'') is an island country in East Asia. It is situated in the northwest Pacific Ocean, and is bordered on the west by the Sea of Japan, while extending from the Sea of Okhotsk in the n ...

, the

United Kingdom The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom (UK) or Britain, is a country in Europe, off the north-western coast of the continental mainland. It comprises England, Scotland, Wales and ...

, the Research Triangle in

North Carolina North Carolina () is a U.S. state, state in the Southeastern United States, Southeastern region of the United States. The state is the List of U.S. states and territories by area, 28th largest and List of states and territories of the United ...

, and

Massachusetts Massachusetts (Massachusett: ''Muhsachuweesut Massachusett_writing_systems.html" ;"title="nowiki/> məhswatʃəwiːsət.html" ;"title="Massachusett writing systems">məhswatʃəwiːsət">Massachusett writing systems">məhswatʃəwiːsət'' En ...

where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based. The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.

Products

Some of the key products that Eisai produces or markets with partners include: *Aciphex/Pariet (

) - Gastroesophageal reflux disease *Actonel ( risedronic acid) - Osteoporosis (Japan) *Aloxi ( palonosetron) - Chemotherapy-induced nausea and vomiting * Aricept ( donepezil) - Mild to moderate dementia for Alzheimer's Disease patients *Banzel/Inovelon ( rufinamide) - Seizures related to Lennox-Gastaut Syndrome *Belviq ( lorcaserin) - Obesity *Dayvigo ( lemborexant) - Insomnia *Fragmin ( dalteparin) - Deep vein thrombosis and pulmonary embolism *Fycompa ( perampanel) - Partial-onset seizures *Halaven ( eribulin) - Metastatic breast cancer *Iomeron ( iomeprol) - Non-ionic contrast medium *Methylcobal ( methylcobalamin) - Peripheral neuropathy *Myonal (

eperisone Eperisone (formulated as the eperisone hydrochloride salt) is an antispasmodic drug. Eperisone acts by relaxing both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement ...

) - Muscle relaxant *Selbex ( teprenone) - Gastric ulcers and gastritis *Zonegran ( zonisamide) - Partial-onset seizures *Gliadel Wafer (

) - Treatment for Brain Tumors *Lenvima ( lenvatinib) - Thyroid Cancer or Kidney Cancer

Aricept

Aricept accounted for 40% of Eisai's revenue as of March 2010. The main competitor to Aricept is a generic formulation from Ranbaxy Labs. Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.

References

External links